1 Li M, "Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance" 57 : 1526-1535, 2008
2 Blüher M, "Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays" 30 : 280-285, 2007
3 Lee TS, "Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection" 110 : 1296-1302, 2004
4 Yang Q, "Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes" 436 : 356-362, 2005
5 Fisher FF, "Serum high molecular weight complex of adiponectin correlates better with glucose intolerance than total serum adiponectin in Indo-Asian males" 48 : 1084-1087, 2005
6 Kannel WB, "Risk stratification in hypertension: new insights from the Framingham Study" 13 : 3S-10, 2000
7 Graham TE, "Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects" 354 : 2552-2563, 2006
8 Takashima N, "Retinol-binding protein 4 and insulin resistance" 355 : 1392-, 2006
9 Janke J, "Retinol binding protein 4 in human obesity" 55 : 2805-2810, 2006
10 Cnop M, "Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex" 46 : 459-469, 2003
1 Li M, "Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance" 57 : 1526-1535, 2008
2 Blüher M, "Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays" 30 : 280-285, 2007
3 Lee TS, "Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection" 110 : 1296-1302, 2004
4 Yang Q, "Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes" 436 : 356-362, 2005
5 Fisher FF, "Serum high molecular weight complex of adiponectin correlates better with glucose intolerance than total serum adiponectin in Indo-Asian males" 48 : 1084-1087, 2005
6 Kannel WB, "Risk stratification in hypertension: new insights from the Framingham Study" 13 : 3S-10, 2000
7 Graham TE, "Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects" 354 : 2552-2563, 2006
8 Takashima N, "Retinol-binding protein 4 and insulin resistance" 355 : 1392-, 2006
9 Janke J, "Retinol binding protein 4 in human obesity" 55 : 2805-2810, 2006
10 Cnop M, "Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex" 46 : 459-469, 2003
11 Wang Y, "Post-translational modification of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex" 281 : 16391-16400, 2006
12 Hara K, "Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome" 29 : 1357-1362, 2006
13 Bowles WH, "Influence of insulin on liver vitamin A in rats" 16 : 704-707, 1967
14 Iwashima Y, "Hypoadiponectinemia is an independent risk factor for hypertension" 43 : 1318-1323, 2004
15 Sasaki H, "High retinol/retinol-binding protein ratio in non insulin-dependent diabetes mellitus" 310 : 177-182, 1995
16 Stefan N, "High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans" 30 : 1173-1178, 2007
17 Nicolai A, "Heme oxygenase-1 induction remodels adipose tissue and improves insulin sensitivity in obesity-induced diabetic rats" 53 : 508-515, 2009
18 Ansell BJ, "Evidence for a combined approach to the management of hypertension and dyslipidemia" 18 : 1249-1257, 2005
19 Adamczak M, "Decreased plasma adiponectin concentration in patients with essential hypertension" 16 : 72-75, 2003
20 Tripathy D, "Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity" 27 : 2204-2210, 2004
21 Wilson PW, "Clustering of metabolic factors and coronary heart disease" 159 : 1104-1109, 1999
22 Broch M, "Circulating retinol binding protein-4, insulin sensitivity, insulin secretion and insulin disposition index in obese and nonobese subjects" 30 : 1802-1806, 2007
23 Thomas F, "Cardiovascular mortality in hypertensive men according to presence of associated risk factors" 37 : 1256-1261, 2001
24 Tan CE, "Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?" 27 : 1182-1186, 2004
25 Lee DC, "Association of serum retinol binding protein 4 and insulin resistance in apparently healthy adolescents" 56 : 327-331, 2007
26 Jungner I, "Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials" 44 : 1641-1649, 1998
27 Jungner I, "Apolipoprotein B and A-I in relation to serum cholesterol and triglyceride in 43,000 Swedish males and females" 21 : 247-255, 1992
28 Baratta R, "Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies" 89 : 2665-2671, 2004
29 Lara-Castro C, "Adiponectin multimeric complexes and the metabolic syndrome trait cluster" 55 : 249-259, 2006